Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476120 | 0.86 | GSK3A (0.33) | GSK3AGSK3B | |
| SCHEMBL8433146 | 0.86 | GSK3A (0.33) | GSK3AGSK3B | |
| SCHEMBL2772030 | 0.79 | — | — | |
| SCHEMBL10589108 | 0.77 | — | — | |
| SCHEMBL10589783 | 0.76 | — | — | |
| SCHEMBL11721418 | 0.73 | — | — | |
| SCHEMBL9230111 | 0.73 | GSK3A (0.31) | GSK3AGSK3B | |
| SCHEMBL17501930 | 0.73 | — | — | |
| SCHEMBL9842155 | 0.72 | ESR2 (0.43) | ALDH1A1PKMHPGDNPSR1 | |
| SCHEMBL9262395 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854601-A | Novel method for preparing 4-diaryl methyl substituted aniline compound by mediation of hexafluoroisopropanol | 湖南理工学院 | 2023-10-10 | — | — | CN | claimed |
| CN-116715591-A | Novel method for preparing 2-diaryl methyl substituted aniline compound by mediation of hexafluoroisopropanol | 湖南理工学院 | 2023-09-08 | — | — | CN | claimed |
| CN-116693404-A | Novel method for preparing 4-diaryl methyl substituted tertiary aromatic amine compound by mediation of hexafluoroisopropanol | 湖南理工学院 | 2023-09-05 | — | — | CN | claimed |
| CN-115368218-B | Method for preparing 4-diaryl methyl substituted phenol compound | 湖南理工学院 | 2024-01-02 | — | — | CN | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230271966-A1 | PRPK INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20130190308-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130178431-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CENTROSE, LLC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8470980-B2 | Extracellular targeted drug conjugates | CENTROSE, LLC (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8361973-B2 | Glycoside compounds and pharmaceutical compositions thereof | CENTROSE, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110319350-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CENTROSE, LLC (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110064752-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064752-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | CES2 243/4885ALDH1A1 1232/4885MAPT 1818/4885 |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | CES2 4078/4885ALDH1A1 162/4885MAPT 4722/4885 |
| US-20230271966-A1 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | CES2 4019/4885ALDH1A1 1333/4885MAPT 1600/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | CES2 2982/4885ALDH1A1 208/4885MAPT 4740/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | CES2 4884/4885ALDH1A1 4698/4885MAPT 3750/4885 |
| US-20130190308-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CES2 2242/4885ALDH1A1 1514/4885MAPT 214/4885 |
| US-20110319350-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UGCG, NFATC1, GAA | CES2 2395/4885ALDH1A1 1948/4885MAPT 3783/4885 |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | CES2 381/4885ALDH1A1 114/4885MAPT 3176/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | CES2 4826/4885ALDH1A1 1303/4885MAPT 1976/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | CES2 4884/4885ALDH1A1 4698/4885MAPT 3750/4885 |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | CES2 3670/4885ALDH1A1 1955/4885MAPT 3924/4885 |
| US-20130178431-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UGCG, NFATC1, GAA | CES2 2395/4885ALDH1A1 1948/4885MAPT 3783/4885 |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | AHR, ARNT, AIPL1 | CES2 3599/4885ALDH1A1 471/4885MAPT 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.